<DOC>
	<DOCNO>NCT01491165</DOCNO>
	<brief_summary>Mainstream current treatment liver cirrhosis liver transplantation , high cost , risk immune rejection issue . Umbilical cord mesenchyma stem cell self-and direct differentiation capacity effectively rescue experimental liver failure contribute liver regeneration , suggest feasibility stem cell transplantation therapy . In study , safety efficacy umbilical cord mesenchyma stem cell transplantation interventional procedure patient liver cirrhosis evaluate .</brief_summary>
	<brief_title>Safety Efficacy Stem Cell Transplantation Treatment Liver Cirrhosis</brief_title>
	<detailed_description>This study include three research center , center carry 25 case liver cirrhosis patient stem cell transplantation . All selection exclusion criterion , data summary analysis complete epidemiological commissioner .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Clinical diagnosis liver cirrhosis ; Without hepatic encephalopathy ; No ascites easily dissipate ascites ; Value bilirubin less 100 ; Value albumin great 16 g / L ; Prothrombin time le 21 second ; Severe cardiovascular disease , immunocompromised patient ; Patients localize lesion affect graft infection ; Coagulation disorder ; Liver nodules 2cm Liver cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>umbilical cord mesenchyma stem cell</keyword>
</DOC>